Pathos AI closed a $237M Series E led by Bristol Myers Squibb, pushing its valuation to $3B — just 17 months after Series D valued it at $1.6B. The signal: BMS isn't making a purely financial bet. It's trading equity for portfolio-wide access to the Pathos Foundry platform plus a three-year exclusive in neuroscience — pharma is starting to treat investing in AI biotech as a shortcut to acquiring in-house agent capability.
Confido Health closed a $12.5M Series A extension led by Z47, bringing its total Series A to $22.5M. The signal: healthcare admin agents don't grow by selling to clinics one at a time — they grow by selling to the private equity funds that own the clinics, then landing the whole portfolio in one motion.
Parakeet Health raised a $10M Series A led by Canvas Ventures, bringing total funding to $13M. The signal: healthcare's fastest path to agent adoption isn't diagnosis — it's the rule-bound, revenue-attributable administrative work like scheduling and recall, where a vendor can win a risk-averse buyer with hard financial numbers instead of a promise about clinical judgment.
GenHealth.ai closed a $16.5M Series A led by healthcare-focused VC Flare Capital Partners, bringing total funding to $30M. This round signals that in healthcare administration — a high-friction, heavily regulated field — the agent narrative VCs will fund has moved from 'a chat assistant that helps look things up' to 'an agent that actually chases down claims and gets paid.'